Advanced search
Publication Cover
Acta Oncologica Volume 41, 2002 - Issue 7-8
Journal homepage
262
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Acute and Late Toxicity Following Adjuvant High-Dose Chemotherapy for High-Risk Primary Operable Breast Cancer A Quality Assessment Study

Inge M. Svane From the Departments of Oncology (I.M. Svane, C. Kamby, D.L. Nielsen, O. Roer, D. Sliffsgaard, S.W. Hansen) and Haematology (H.E. Johnsen), Herlev Hospital, University of Copenhagen, Denmark and the Department of Clinical Immunology, Odense University Hospital, Denmark (K.M. Homburg)
,
Keld M. Homburg From the Departments of Oncology (I.M. Svane, C. Kamby, D.L. Nielsen, O. Roer, D. Sliffsgaard, S.W. Hansen) and Haematology (H.E. Johnsen), Herlev Hospital, University of Copenhagen, Denmark and the Department of Clinical Immunology, Odense University Hospital, Denmark (K.M. Homburg)
,
Claus Kamby From the Departments of Oncology (I.M. Svane, C. Kamby, D.L. Nielsen, O. Roer, D. Sliffsgaard, S.W. Hansen) and Haematology (H.E. Johnsen), Herlev Hospital, University of Copenhagen, Denmark and the Department of Clinical Immunology, Odense University Hospital, Denmark (K.M. Homburg)
,
Dorte L. Nielsen From the Departments of Oncology (I.M. Svane, C. Kamby, D.L. Nielsen, O. Roer, D. Sliffsgaard, S.W. Hansen) and Haematology (H.E. Johnsen), Herlev Hospital, University of Copenhagen, Denmark and the Department of Clinical Immunology, Odense University Hospital, Denmark (K.M. Homburg)
,
Ole Roer From the Departments of Oncology (I.M. Svane, C. Kamby, D.L. Nielsen, O. Roer, D. Sliffsgaard, S.W. Hansen) and Haematology (H.E. Johnsen), Herlev Hospital, University of Copenhagen, Denmark and the Department of Clinical Immunology, Odense University Hospital, Denmark (K.M. Homburg)
,
Dorte Sliffsgaard From the Departments of Oncology (I.M. Svane, C. Kamby, D.L. Nielsen, O. Roer, D. Sliffsgaard, S.W. Hansen) and Haematology (H.E. Johnsen), Herlev Hospital, University of Copenhagen, Denmark and the Department of Clinical Immunology, Odense University Hospital, Denmark (K.M. Homburg)
,
Hans E. Johnsen From the Departments of Oncology (I.M. Svane, C. Kamby, D.L. Nielsen, O. Roer, D. Sliffsgaard, S.W. Hansen) and Haematology (H.E. Johnsen), Herlev Hospital, University of Copenhagen, Denmark and the Department of Clinical Immunology, Odense University Hospital, Denmark (K.M. Homburg)
&
Steen W. Hansen From the Departments of Oncology (I.M. Svane, C. Kamby, D.L. Nielsen, O. Roer, D. Sliffsgaard, S.W. Hansen) and Haematology (H.E. Johnsen), Herlev Hospital, University of Copenhagen, Denmark and the Department of Clinical Immunology, Odense University Hospital, Denmark (K.M. Homburg)
 show all
Pages 675-683 | Published online: 08 Jul 2009

  • Peters WP, Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as con-solidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-43.
  • Peters WP, Shpall EJ, Jones RB, et al. High-dose combina-tion alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368-76.
  • Bergh J, Wiklund T, Erikstein B, et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrowsupported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 2000; 356: 1384-91.
  • Hortobagyi GN, Buzdar AU, Theriault RL, et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 2000; 92: 225-33.
  • Rodenhuis S, Botenbal M, Beex L. Randomized phase III study of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes. Proc ASCO 2000; 19: 74a (Abstr).
  • Rodenhuis S, Richel DJ, van der Wall E, et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 1998; 352: 515-21.
  • Peters WP, Rosner G, Vredenburgh J, et al. Updated results of a prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): CALGB 9082/SWOG 9114/NCIC Ma-13. Proc ASCO 2001; 20: 21a (Abstr).
  • Gianni L, Bonadonna G. Five-year result of the randomized clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with > 3 positive nodes (LN+). Proc ASCO 2001; 21a (Abstr).
  • Glimelius B, Bergh J, Brandt L, et al. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types-summary and conclusions. Acta Oncol 2001; 40: 13554.
  • Norton L. High-dose chemotherapy for breast cancer: 'how do you know? J Clin Oncol 2001; 19: 2769-70.
  • Antman KH. A critique of the eleven randomised trials of high-dose chemotherapy for breast cancer. Eur J Cancer 2001 ; 37: 173-9.
  • Rodenhuis S. High-dose chemotherapy in breast cancer-interpretation of the randomized trials. Anticancer Drugs 2001; 12: 85-8.
  • Gianni L. High-dose chemotherapy for breast cancer any use for it? Ann Oncol 2002; 13: 650-2.
  • Schrama JG, Faneyte IF, Schornagel JH, et al. Randomized trial of high-dose chemotherapy and hematopoietic progeni-tor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol 2002; 13: 689-98.
  • Serke S, Johnsen HE. A European reference protocol for quality assessment and clinical validation of autologous haematopoietic blood progenitor and stem cell grafts. Bone Marrow Transplant 2001; 27: 463-70.
  • Moss TJ, Sanders DG, Lasky LC, Bostrom B. Contamination of peripheral blood stem cell harvests by circulating neurob-lastoma cells. Blood 1990; 76: 1879-83.
  • Kvalheim G. Detection of occult tumour cells in bone mar-row and blood in breast cancer patients-methods and clini-cal significance. Acta Oncol 1996; 35 (Suppl 8): 13-8.
  • Fields KK, Elfenbein GJ, Trudeau WL, Perkins JB, Janssen WE, Moscinski LC. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 1996; 14: 1868-76.
  • Cady B. Total mastectomy and partial axillary dissection. Surg Clin North Am 1973; 53: 313-8.
  • Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer (a study of 1 409 cases of which 359 have been followed for IS years). Br J Cancer 1957; 11: 359-64.
  • Antman K, Ayash L, Elias A, et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable ad-vanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102-10.
  • Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997; 337: 949-55.
  • van der WE, Nooijen WJ, Baars JW, et al. High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach. Br J Cancer 1995; 71: 857-62.
  • Knudsen LM, Gaarsdal E, Jensen L, Nikolaisen K, Johnsen HE. Evaluation of mobilized CD34+ cell counts to guide timing and yield of large-scale collection by leukapheresis. J Hematother 1998; 7: 45-52.
  • Richel DJ, Johnsen HE, Canon J, et al. Highly purified CD34 + cells isolated using magnetically activated cell selection provide rapid engraftment following high-dose chemotherapy in breast cancer patients. Bone Marrow Trans-plant 2000; 25: 243-9.
  • Naume B, Borgen E, Beiske K, et al. Immunomagnetic tech-niques for the enrichment and detection of isolated epithelial cells in bone marrow: non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase. J Hematother 1997; 6: 103-14.
  • Naume B, Borgen E, Nesland JM, et al. Increased sensitivity for detection of micrometastases in bone-marrow/peripheralblood stem-cell products from breast-cancer patients by negative immunomagnetic separation. Int J Cancer 1998; 78: 556-60.
  • Borgen E, Naume B, Nesland JM, et al. The European ISHAGE Working Group for Standardization of Tumor Cell Detection. Standardization of immunocytochemical detection of cancer cells in BM and blood: establishment of objective criteria for the valuation of immunostained cells. Cytotherapy 1999; 1: 377-88.
  • Borgen E, Beiske K, Trachsel S, et al. Immunocyto-chemical detection of isolated epithelial cells in bone marrow: non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase. J Pathol 1998; 185: 42734.
  • Denis MG, Lipart C, Leborgne J, et al. Detection of dissemi-nated tumor cells in peripheral blood of colorectal cancer patients. Int J Cancer 1997; 74: 540-4.
  • Bartek J, Taylor-Papadimitriou J, Miller N, Millis R. Patterns of expression of keratin 19 as detected with monoclonal antibodies in human breast tissues and tumours. Int J Cancer 1985; 36: 299-306.
  • Peto R, Collins R, Sackett D, et al. The trials of Dr Bernard Fisher a European perspective on an American episode. Control Clin Trials 1997; 18: 1-13.
  • Rodenhuis S, Baars JW, Schornagel JH, et al. Feasibility and toxicity study of a high-dose chemotherapy regimen for auto-transplantation incorporating carboplatin, cyclophosphamide and thiotepa. Ann Oncol 1992; 3: 855-60.
  • Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001; 19: 602-11.
  • Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001; 344: 1997-2008.
  • van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90: 210-8.
  • Schagen SB, Hamburger HL, Muller MJ, Boogerd W, van Dam FS. Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol 2001; 51: 159-65.
  • Fanfulla F, Pedrazzoli P, Da Prada GA, et al. Pulmonary function and complications following chemotherapy and stem cell support in breast cancer. Eur Respir J 2000; 15: 56-61.
  • Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-9.
  • Cooper BW, Moss TJ, Ross AA, Ybanez J, Lazarus HM. Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplan-tation in patients with metastatic breast cancer. J Clin Oncol 1998; 16: 3509-17.
  • Weaver CH, Moss T, Schwartzberg LS, et al. High-dose chemotherapy in patients with breast cancer evaluation of infusing peripheral blood stem cells containing occult tumor cells. Bone Marrow Transplant 1998; 21: 1117-24.
  • Gluck S, Ross AA, Layton TJ, et al. Decrease in tumor cell contamination and progenitor cell yield in leukapheresis products after consecutive cycles of chemotherapy for breast can-cer treatment. Biol Blood Marrow Transplant 1997; 3: 316-23.
  • Lemieux J, Cantin G, Delage R, et al. High dose chemotherapy with stem-cell rescue compared to standard chemother-apy in high risk breast cancer: a retrospective analysis. Proc ASCO 2002; 21: 283b (Abstr).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.